Barcelona, Spain. New data presented at the EULAR meeting (European League Against Rheumatism) demonstrate that MabThera's (rituximab) effectiveness in relieving patients of the distressing ...

Roche’s cancer and inflammatory diseases drug, MabThera (rituximab), finally faces biosimilar competition in Europe, four years after its patent expired. The Swiss pharma has enjoyed several ...

Washington, U.S. -- Data presented at this year's American College of Rheumatology Congress (ACR) show that patients receiving repeat treatment with MabThera/Rituxan (rituximab) achieved continued ...

The company’s blockbuster oncology drugs are Avastin, Herceptin and MabThera/Rituxan. These three drugs alone accounted for roughly 40% of the company’s overall revenues in 2016. However ...

MabThera shown to be effective and well tolerated over the long-term A study has shown that rheumatoid arthritis patients given multiple courses of MabThera experienced further improvements in ...

The Story behind Roche Holding's Valuation—and What's Driving It (Continued from Prior Part) MabThera, a key product for Roche MabThera is branded as Rituxan in the US and Japan. It’s ...

Roche Holding AG said on Wednesday that cancer drug MabThera, its biggest-selling product, also helps alleviate symptoms related to rheumatoid arthritis, a finding that significantly boosts the ...

NEW YORK Roche will present results of a study of its arthritis medication MabThera at a four-day meeting of the European League Against Rheumatism in Paris that begins Wednesday. The company ...

LONDON (CBS.MW) -- Swiss drugmaker Roche on Tuesday said it will amend the trial of MabThera, a drug treating relapsed indolent non-Hodgkin's lymphoma, after a Phase III study on the drug finished ...

Following Herceptin earlier this year, Roche has announced that tampered vials of it's blood cancer drug MabThera (Rituxan) were found in Germany. Swiss drugmaker Roche said on Friday that ...

ZURICH (Reuters) - Roche Holding AG said on Friday its top-selling cancer drug MabThera helped patients with Chronic Lymphocytic Leukaemia (CLL) to live longer without their disease getting worse ...

Basel, 15 March 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved MabThera® (rituximab) for the treatment of adults with moderate to severe ...